Helicobacter pylori cag Pathogenicity Island and Gastric Carcinogenesis

幽门螺杆菌致病岛与胃癌发生

基本信息

  • 批准号:
    8413059
  • 负责人:
  • 金额:
    $ 21.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-01-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

Persistent colonization of the human stomach with the Gram-negative bacterium Helicobacter pylori is associated with an increased risk for the development of gastric adenocarcinoma. H. pylori isolates from different humans exhibit a considerable level of genetic diversity. One chromosomal region that is present in some H. pylori strains but not others is the cag pathogenicity island (PAI), a 40 kb region that is predicted to encode 27 different proteins. H. pylori strains harboring the cag pathogenicity island are associated with a significantly higher rate of gastric cancer incidence than are strains that lack the cag pathogenicity island. The cag PAI encodes an effector protein, CagA, that is translocated into epithelial cells via a type IV secretion process. The long-term goal of this work is to define mechanisms through which H. pylori cag PAI-positive strains induce gastric cancer. Recent studies in our laboratory have revealed an important role of salt in regulating CagA expression and in modulating the ability of H. pylori to cause aberrant epithelial cell responses. These findings, in conjunction with extensive literature indicating a role of dietary salt in gastric cancer, have led us to propose experiments that investigate the mechanism by which salt modulates CagA expression, investigate effects of salt on H. py/ori-induced cell signaling in vitro, and investigate effects of salt on H. py/on-induced disease progression in vivo. Aim 1 proposes to analyze the regulatory mechanisms through which salt regulates expression of CagA. We will use multiple experimental approaches, including introduction of genetic mutations into H. pylori, isolation of DNA-protein complexes, and mass spectrometry analysis of such complexes. Aim 2 will investigate alterations in gastric epithelial cells that occur in response to H. pylori strains that express mutant forms of CagA. Phenotypes selected for analysis will include translocation of CagA into host cells, induction of IL-8 secretion, (3-catenin activation and EGFR transactivation (in collaboration with Drs. Peek and Polk, respectively), and apoptosis, since each of these phenotypes is relevant to the pathogenesis of gastric cancer. Aim 3 will extend these in vitro results into rodent models of H. py/or/-induced cancer that have been developed by Dr. Peek, including INS-GAS mice and Mongolian gerbils. These studies should lead to important advances in our understanding of the molecular mechanisms by which H. pylori modulates signaling in gastric epithelial cells and stimulates the development of gastric cancer. Ultimately, these studies should lead to advances in the prevention and therapy of malignancies that develop in the setting of chronic inflammation.
革兰氏阴性细菌幽门螺杆菌在人胃中的持续定植是 与胃腺癌发生风险增加相关。H.幽门螺杆菌分离株, 不同的人类表现出相当程度的遗传多样性。一个染色体区域, 在一些H. pylori菌株,而不是其他菌株的cag致病岛(派),一个40 kb的区域,预计 编码27种不同的蛋白质H.携带cag致病岛的pylori菌株与 胃癌发病率明显高于缺乏cag致病岛的菌株。 cag派编码一种效应蛋白CagA,其通过IV型胶原转运到上皮细胞中。 分泌过程。 这项工作的长期目标是确定H。pylori cag PAI阳性菌株 诱发胃癌。我们实验室最近的研究揭示了盐在调节 CagA的表达及调节H.幽门螺杆菌引起异常的上皮细胞反应。这些 研究结果,结合大量的文献表明饮食中的盐在胃癌中的作用,使我们 提出研究盐调节CagA表达的机制的实验, 研究盐对H. py/ori体外诱导的细胞信号转导,并研究盐对H. py/on诱导的体内疾病进展。 目的1分析盐对CagA表达的调控机制。我们 将使用多种实验方法,包括将基因突变引入H。幽门,分离 的DNA-蛋白质复合物,和这种复合物的质谱分析。目标2将调查 胃上皮细胞对H.表达突变形式的幽门螺杆菌菌株 CagA。选择用于分析的表型将包括CagA易位到宿主细胞中,诱导IL-8 分泌、β-连环蛋白激活和EGFR反式激活(与Peek和Polk博士合作, 和细胞凋亡,因为这些表型中的每一种都与胃溃疡的发病机制有关。 癌目的3将这些体外结果推广到H. py/或/-诱导的癌症, Peek博士开发的实验动物,包括INS-GAS小鼠和蒙古沙鼠。 这些研究应该导致我们对分子机制的理解取得重要进展, 其中H。幽门螺杆菌调节胃上皮细胞的信号传导并刺激胃上皮细胞的发育。 癌最终,这些研究将导致恶性肿瘤预防和治疗的进展 在慢性炎症的情况下发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIMOTHY L COVER其他文献

TIMOTHY L COVER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIMOTHY L COVER', 18)}}的其他基金

Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    10250299
  • 财政年份:
    2019
  • 资助金额:
    $ 21.07万
  • 项目类别:
Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    10454894
  • 财政年份:
    2019
  • 资助金额:
    $ 21.07万
  • 项目类别:
Type IV Protein Secretion in Helicobacter pylori
幽门螺杆菌中 IV 型蛋白的分泌
  • 批准号:
    10390377
  • 财政年份:
    2016
  • 资助金额:
    $ 21.07万
  • 项目类别:
Type IV Protein Secretion in Helicobacter pylori
幽门螺杆菌中 IV 型蛋白的分泌
  • 批准号:
    10595676
  • 财政年份:
    2016
  • 资助金额:
    $ 21.07万
  • 项目类别:
Type IV Protein Secretion in Helicobacter pylori
幽门螺杆菌中 IV 型蛋白的分泌
  • 批准号:
    10218960
  • 财政年份:
    2016
  • 资助金额:
    $ 21.07万
  • 项目类别:
Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    7930158
  • 财政年份:
    2010
  • 资助金额:
    $ 21.07万
  • 项目类别:
Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    8397541
  • 财政年份:
    2010
  • 资助金额:
    $ 21.07万
  • 项目类别:
Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    8195842
  • 财政年份:
    2010
  • 资助金额:
    $ 21.07万
  • 项目类别:
Pathogenesis of Helicobacter pylori infection
幽门螺杆菌感染的发病机制
  • 批准号:
    8259073
  • 财政年份:
    2010
  • 资助金额:
    $ 21.07万
  • 项目类别:
Regulation of H. Pylori Virulance by Dietary Factors that Impact Gastric Cancer
影响胃癌的饮食因素对幽门螺杆菌毒力的调节
  • 批准号:
    9274163
  • 财政年份:
    2009
  • 资助金额:
    $ 21.07万
  • 项目类别:

相似海外基金

New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections
IFN诱导的OAS蛋白在针对细菌感染的先天免疫防御中的新作用
  • 批准号:
    10649771
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
Derivation and validation of a clinical prediction rule to identify febrile infants 61 to 90 days old at low and non-negligible risk of invasive bacterial infections
推导和验证临床预测规则,以识别 61 至 90 天大的发热婴儿,其侵袭性细菌感染的风险较低且不可忽略
  • 批准号:
    10574286
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
Structural and functional studies of YbtPQ for fighting bacterial infections
YbtPQ 对抗细菌感染的结构和功能研究
  • 批准号:
    10644889
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
A gut feeling: How can gastrointestinal bacterial infections alter female reproductive tract immunity and control of sexually transmitted infections
直觉:胃肠道细菌感染如何改变女性生殖道免疫力和性传播感染的控制
  • 批准号:
    MR/X031993/1
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Research Grant
Molecular probes to diagnose pathoadapatations in bacterial infections
诊断细菌感染病理适应的分子探针
  • 批准号:
    EP/X014479/1
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Research Grant
Using Small Area Variation Analysis to Investigate Sources of Practice Variation for Febrile Infants at Risk for Invasive Bacterial Infections
使用小面积变异分析来调查有侵袭性细菌感染风险的发热婴儿的实践变异来源
  • 批准号:
    10588846
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
宿主定向 Orynotide 用于治疗耐多药革兰氏阴性细菌感染
  • 批准号:
    10674221
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
SimCell vaccines against Staphylococcus aureus bacterial infections
针对金黄色葡萄球菌细菌感染的 SimCell 疫苗
  • 批准号:
    10073241
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Grant for R&D
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Standard Grant
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了